PSivida

Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA

...acquire a majority stake in Medidur(TM) FA, the company's Phase III investigative treatment for diabetic macular edema (DME), from development partner psivida Ltd (Nasdaq: PSDV , ASX: PSD, Xetra: PSI) and fund the remaining development obligations for the product. Under the new agreement, Alimera will ass...

DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME

...the recruitment phase of this pivotal study," said psivida Limited Managing Director, Dr. Paul Ashton. Curre...ease visit http://www.alimerasciences.com About psivida Limited pSivida, a Boston, MA. based global drug ...) technology which underpins the Medidur product. psivida owns the rights to develop and commercialize a mod...

PSivida, Pfizer Ink $165 Million Licensing Pact

... Perth-based bio-nanotech major, psivida Limited has signed an exclusive worldwide Collabor...lications. Under the terms of the agreement, psivida will receive up to $155 million in development and...laboration in ophthalmic applications and will pay psivida a royalty on net sales of those products. I...

PSivida in Medical Technology

Enrollment Complete in Pivotal Phase 3 Trial of Medidur(TM) FA for Diabetic Macular Edema

...vately held ophthalmic pharmaceutical company, and psivida Limited (Nasdaq: PSDV; ASX: PSD; Xetra: PSI), anno...ficacy assessed at two years. Alimera Sciences and psivida are jointly developing Medidur FA under a collabor...ease visit http://www.alimerasciences.com About psivida Limited ...

Enrollment Begins on Human PK Study for Medidur(TM) FA

...vately held ophthalmic pharmaceutical company, and psivida Limited (Nasdaq: PSDV , ASX: PSD, Xetra: PSI) tod...ls in the anterior chamber." Alimera Sciences and psivida Limited have a worldwide agreement to co-develop a...r," said Dr Paul Ashton, PhD, Managing Director of psivida Limited. "Additionally, by determining anterior ch...

PSivida in Biological Technology

Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement

ATLANTA and BOSTON, March 17 /PRNewswire-FirstCall/ -- Alimera Sciences and pSivida Ltd (Nasdaq: PSDV ; ASX: PSD; Xetra: PSI) today announced that they have amended their license and collaboration agreement relating to Medidur(TM) FA, the companies' Phase III investigative treatment for diabe...